FDA staffers sue agency over email surveillance


Six of the so-called "FDA 9" whistleblowers are suing the federal watchdog agency, alleging that the government violated their constitutional rights with surveillance of their private email accounts.

The staffers allege that the FDA spied on the private email accounts they accessed using their government-issued computers, after they warned Congress and the president that unsafe medical devices were being allowed onto the U.S. market.

The lawsuit, filed in the U.S. District Court for the District of Columbia, levels 12 counts against the agency, its chief Dr. Margaret Hamburg, medical device chief Dr. Jeffrey Shuren, the Dept. of Health & Human Services and its head, Kathleen Sebelius, and other government officials. It accuses them of enacting the secret surveillance after learning of a letter the staffers sent to then-President-elect Barack Obama’s transition team Jan. 7, 2009, and of using the information gleaned from the tapped email accounts to harass and, in some cases, fire the whistleblowers.

After learning of the letter, the FDA set up a secret file on its database labelled "FDA 9" to collect the surveillance data. The agency took screenshots of the staffers’ computers as they accessed their private Gmail accounts, according to the lawsuit. Although the government has the right to surveil any activity on the computers it issues, it’s unclear whether it’s legal to secretly gain access to private email accounts used on government-issued devices.

The staffers later wrote an open letter to Obama asking him to hold former and current officials accountable for their alleged wrongdoing. The Jan. 7 letter to John Podesta, the transition team leader, warned that potentially unsafe radiological devices were being allowed to hit the market.

"For example, in the January 7, 2009 letter to Mr. Podesta, the FDA scientists noted that in the past, computer-aided detection devices (‘CAD’) to be used with breast mammograms were not safe or effective, but the FDA approved the devices anyway in a flawed process that ignored the science. This has led to significant harm to large numbers of women and significant unnecessary costs to the public," according to the lawsuit. "After the defendants learned about the Jan. 7, 2009, letter to Mr. Podesta, FDA officials began to secretly refer to the signatories of the letter from the FDA scientists and including [the plaintiffs] as the ‘FDA Nine’ or ‘FDA 9.’"

The FDA staffers also communicated with aides of Sen. Charles Grassley (R-Iowa), who then warned the FDA not to retaliate against the whistleblowers.

But, "despite Senator Grassley’s warnings," the agency "commenced a covert and secret search and seizure operation on the ‘FDA Nine’ in retaliation for their protected speech, which included, but was not limited to, the interception of private communications sent by or on behalf of plaintiffs to congressional representatives," according to the lawsuit.

"The information secretly obtained by defendants included plaintiffs’ legally protected documents and information that was stored by plaintiffs in folders labeled ‘For Congress’ and other folders that clearly indicated the intent of plaintiffs to raise issues of public concern with appropriate authorities," according to the complaint.

"Defendants have taken and converted private emails without due process or just compensation in violation of the 5th Amendment of the United States Constitution. Defendants have initiated searches and seizures in violation of the 1st and 4th Amendments. Defendants have conducted searches and seizures of a scope that violates the 1st and 4th Amendments. Defendants have violated the 1st Amendment by chilling free speech with searches and seizures. Defendants have violated the 1st Amendment by chilling Plaintiffs’ and the public’s right to associate with whistleblowers. Defendants have violated plaintiffs’ right to representation. Defendants have chilled plaintiffs’ protected 1st Amendment right to free speech."

Documents obtained by the Washington Post show that the FDA twice asked the HHS inspector general’s office to investigate the whistleblowers, accusing them of illegally releasing confidential business information about the devices they believed were unsafe.

"We have obtained new information confirming the existence of information disclosures that undermine the integrity and mission of the FDA and, we believe, may be prohibited by law," Shuren wrote, according to the documents.

But both times the IG’s office declined to intervene.

"Who would have thought that they would have the nerve to be monitoring my communications to Congress?" Robert Smith, one of the plaintiffs in the suit, told the Post. "How dare they?"

Michael Sussmann, a former federal prosecutor who is now a partner at the Perkins Coie law firm, told the newspaper that the FDA has the latitude to conduct extensive monitoring.

"Anything on this agency’s network is fair game by use of this banner, as long as they’re lawfully targeting their employee," Sussman said.

Federal investigators later cleared the FDA managers of criminal acts against the whistleblowers.

“We do have a zero tolerance policy for retaliation,” Shuren said at the time.

"The FDA has a huge responsibility to protect public health and safety," Grassley said in a statement to the Post. "It’s hard to see how managers apparently thought it was a good use of time to shadow agency scientists and monitor their e-mail accounts for legally protected communications with Congress."

RSS From Medical Design & Outsourcing

  • Molex delivers ISO 13485-compliant, medical-grade surgical cables from its class 100,000 clean room facility
    Molex, LLC operates a fully ISO 146441-1:1999 Class 8-certified clean room, satisfying strict particulate contamination levels specified by ISO-compliant requirements. Located in Thailand, the facility has less than 100,000 particulates (≥0.5µm) per cubic foot of air and manufactures a variety of ISO 13485-compliant medical cables and surgical cables used in operating theatres, hospitals, laboratories and […]
  • Swept-Source OCT: Patent license agreement between Massachusetts General Hospital and Heidelberg Engineering
    Heidelberg Engineering has entered into a patent license agreement with Massachusetts General Hospital (MGH) in Boston. The agreement grants global and exclusive rights to 77 basic patents and patent applications which relate to swept-source OCT technology and its application in ophthalmology. Spectral domain OCT has become indispensable to eye care professionals worldwide to diagnose and […]
  • MIT’s MultiFab presents a stark challenge to incumbent 3D Printer manufacturers’ hardware, software, and business Models
    MIT’s Computational Fabrication Group recently announced the MultiFab, a low-cost 3D printer that can combine up to 10 different resins in one part and also includes a 3D scanning system to identify and fix errors during production. According to Lux Research, these capabilities are rare in commercial 3D printers today due to the manufacturers’ need […]
  • AVX releases Accu-P MP medical grade film chip capacitors for medical devices
    AVX Corporation, a leading manufacturer of passive components and interconnect solutions, has released a new series of thin film chip capacitors specifically designed to meet the demanding performance specifications for implantable medical devices. Delivering extremely tight capacitive tolerances, exceptionally repeatable performance, and remarkably low ESR and high Q at high frequencies—including VHF, UHF, and RF […]
  • RIVANNA commences manufacturing of its Accuro device
    Rivanna Medical announced that it has begun manufacturing its FDA-cleared Accuro device, a handheld and untethered smart-phone-sized device that is designed to guide spinal anesthesia with automated 3D navigation technology in addition to ultrasound imaging of abdominal, musculoskeletal, cardiac and peripheral vascular anatomies. The product will be launched at the ASA annual meeting in San […]
  • FDA seeks public input on Quality Metrics guidance
    by Oliver Wolf, Senior Product Manager, MasterControl In line with the general shift towards risk-driven approaches in the quality management world, FDA is now taking steps towards applying those same principles to its own auditing schedule. At the end of July, the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation […]
  • First ‘Ear Wear’ for Active Adults Debuts with MDHearingAid FIT
    If you’ve burned out your ears with earbuds, headphones or decades of other audio abuse but aren’t ready for your grandmother’s hearing aids, not to worry! The new MDHearingAid FIT gets you back in the game with a tiny, FDA-registered, one-size-fits-most solution that doesn’t block your ear canal like old-fashioned in-the-ear hearing aids. The FIT feels […]
  • CardioGenics enters into manufacturing agreement with Ontario-based Plasticap
    CardioGenics Holdings, developer for the In-Vitro-Diagnostics (“IVD”) testing market, announced that it has entered into a manufacturing agreement with Plasticap of Ontario, Canada, pursuant to which Plasticap will manufacture CardioGenics’ proprietary self-metering cartridges for its QL Care analyzer. The term of the agreement is three years and the purchase price for each cartridge shall be […]
  • MTD Micro Molding releases micro materials menu
    MTD Micro Molding, a long-time leader in micro-injection molding, has released an updated “Materials Menu” of materials that can be successfully micromolded to help guide engineers at medical device companies. Material selection is a crucial step in product manufacturability. The correct material drives tolerance, dimension, strength, usabality, speed-to-market, design, critical features, and cost. Through MTD’s […]
  • MedTech Chat: Elastic technology for drug delivery
    Dr. Zhen Gu and Dr. Yong Zhu from North Carolina State University are both co-senior authors of a research paper describing their recent work. Dr. Gu, Dr. Zhu and other researchers from North Carolina State University and the University of North Carolina at Chapel Hill have developed a drug delivery technology that consists of an […]
  • B. Braun’s OEM Division offers large bore normally closed low-pressure check valves
    Infusion therapy and pain management device manufacturer B. Braun said today it is offering normally closed large-bore low-pressure check valves through its valve-focused contract manufacturing OEM division. The valves, offered by Bethlehem, Pa.-based B. Braun, are designed for the intermittent injection of fluids during medical treatment and open automatically when pressure is applied. The newly […]

Leave a Reply